Search
carfilzomib (YU101, CFZ, Kyprolis)
Indications:
- relapsed & refractory multiple myeloma
Adverse effects:
- thrombocytopenia
- anemia
- lymphopenia
- neutropenia
- pneumonia
- fatigue
- hyponatremia
Mechanism of action:
- inhibits proteasome
- irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome
- inhibition of proteasome-mediated proteolysis results in a build-up of polyubiquinated proteins, which may cause:
- cell cycle arrest
- apoptosis
- inhibition of tumor growth
Notes:
- cost: $10,000 per 28 day cycle
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=11556711
References
- Wikipedia: Carfilzomib
http://en.wikipedia.org/wiki/Carfilzomib